Duration-Dependent Efficacy and Clinical Safety of Repeated Low-Level Red-Light Therapy for Paediatric Myopia: A Systematic Review and Meta-Analysis
Lin LY, Hsu CH, Su H, Sun JW, Wu JS, Jeng WJ, Tsai CH, Yuliani FS, Lin SH
Clinical & experimental ophthalmology · 2 citas
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2026-03-18 · Clin Exp Ophthalmol · vol. 54 · número 5 · págs. 630–652
- Editorial
- Wiley
- Citado
- 2 citas · más que el 94% de estudios similares · 5.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 57 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY-NC-ND
- Áreas de investigación
- Ophthalmology and Visual Impairment Studies · Corneal surgery and disorders · Retinopathy of Prematurity Studies
- Palabras clave
- Patient safety, MEDLINE, Clinical trial, Adverse effect, Safety profile
- MeSH
- humans, myopia, refraction, ocular, treatment outcome, visual acuity, child, randomized controlled trials as topic, axial length, eye, low-level light therapy, red light
9 autores
- Lee‐Yuan Lin🇹🇼Taipei Medical University
- Cheng‐Hao Hsu🇹🇼Taipei Medical University
- Hung Chang Su🇹🇼Taipei Medical University
- Ji Sun🇹🇼Taipei Medical University
- Jie‐Syuan Wu🇹🇼Taipei Medical University
- Wei‐Jung Jeng🇹🇼Taipei Medical University
- Chen‐Hsin Tsai🇹🇼Taipei Medical University Hospital
- Fara Silvia Yuliani🇮🇩Universitas Gadjah Mada
- Shyh‐Hsiang Lin🇹🇼 · autor de correspondenciaTaipei Medical University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Repeated low-level red-light (RLRL) therapy is a novel, non-invasive intervention for controlling paediatric myopia progression. Despite increasing clinical use, questions remain regarding the magnitude, durability, and safety of treatment effects. This study evaluated its efficacy and safety based on randomised controlled trial (RCT) evidence.
Methods
PubMed, Embase, and the Cochrane Library were searched through August 2025 for RCTs comparing RLRL with control in children (< 18 years). The primary outcome was spherical equivalent refraction (SER); secondary outcomes included axial length (AL), choroidal thickness (ChT), anterior chamber depth (ACD), central corneal thickness (CCT), lens thickness (LT), and uncorrected visual acuity (UCVA). Evidence certainty was assessed using the GRADE framework.
Results
Twenty-eight RCTs (3573 participants) were included. RLRL therapy achieved duration-dependent myopia control (p < 0.05), with pooled improvements versus control at 12 months of +0.68 D in SER, -0.30 mm in AL, and +26.7 μm in ChT. Subgroup analysis showed greater efficacy in children with higher baseline myopia (p < 0.0001), with comparable effects between 5- and 7-day regimens. UCVA was higher with RLRL therapy. ACD, CCT, and LT were unchanged. Reported adverse events were mild and transient, with no consistent structural or functional abnormalities described.
Conclusions
RLRL was associated with duration-dependent reductions in myopia progression up to 1 year. Reported structural parameters remained stable and adverse events were generally mild. Moderate-certainty evidence supports improvement in SER and ChT, whereas evidence for AL remains of lower certainty. Longer-term trials incorporating comprehensive retinal safety assessment are required.
Trial registration
PROSPERO CRD420251112677.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.